The global landscape of sleep medicine is currently witnessing a paradigm shift, transitioning from a focus on primary respiratory disorders toward a comprehensive management model of neurological and sleep-disordered breathing conditions. Central to this evolution is the strategic acquisition of Noctrix Health, Inc. by ResMed (NYSE: RMD), a transaction valued at approximately $340 Million. This acquisition, announced during ResMed’s third-quarter fiscal year 2026 earnings ca

This report provides strategic foresight into five dominant mega trends shaping the European HealthTech and MedTech landscape for 2026. The year marks a critical nexus where groundbreaking technological acceleration meets definitive regulatory enforcement, primarily through the EU AI Act and the European Health Data Space (EHDS) regulation.